SloveniaSlovenia

Barr to purchase Pliva for $2.2 billion, beating rival Actavis

21.07.2006

Zagreb – In the bidding race between the Icelandic Actavis Group and US Barr Pharmaceuticals Inc. for the takeover of the Croatian biogenerics producer Pliva d.d., the company ultimately opted for Barr’s offer. Both companies’ offers have been carefully reviewed by Pliva’s Supervisory and Management Boards, who have been advised by Deutsche Bank.
Under the terms of Barr’s proposal, Pliva’s shareholders will receive HRK705 (Euro99) in cash for each Pliva share held. Shareholders will additionally be entitled to a dividend of HRK12 (Euro1.70) per share, which values the whole deal at some $2.2 billion (Euro1.7 billion). The proposal is conditional upon antitrust approvals in Germany and the US. Barr’s offer price represents a 81-percent premium to Pliva’s average share price of HRK389 (Euro54.50) per ordinary share for the twelve months to 16 March 2006, the day before Pliva received the initial indicative non-binding proposal from Actavis of HRK 630 (Euro88) per Pliva share.
The combination of Pliva and Barr will expand geographic coverage and create a global pharmaceutical giant with annual revenues of about $2.5bn (Euro2bn).
The enlarged company will have a fully integrated generics platform with manu-facturing, development and marketing expertise, with a low-cost manufacturing base situated in eastern Europe and an extensive European and North American distribution and sales network.

SloveniaSlovenia

05.03.2010

Ljubljana – Slovenian drugmaker Krka d.d. turned in a solid performance in 2009, with total sales reaching EUR950m, similar to turnover in 2008. Profits rose by around 10% year-on-year to EUR173.7m. The results announced at the...

SloveniaSlovenia

27.08.2009

Ljubljana – Pharma giants Warner-Lambert and Pfizer have withdrawn their lawsuit against the Slovenian generic manufacturer Krka d.d over the infringement of two patents concerning their US$12bn blockbuster drug Lipitor...

SloveniaSlovenia

29.04.2009

Ljubljana – BIA Separations d.o.o., the Slovenian specialist for downstream processing of biologicals using monoliths, has received an EUR8m cash injection from the European Investment Bank (EIB). EIB president Philippe Maystadt...

SloveniaSlovenia

21.02.2009

Ljubljana – The most talented young synthetic biologists currently seem to be coming from Eastern Europe. After its success in 2006, a team of young undergraduate chemists from the University of Ljubljana has once again won the...

SloveniaSlovenia

01.11.2008

Belgrade/Lund – Swedish developer of probiotic bacteria Probi AB (Lund) has signed a distribution agreement with Serbian pharmaceutical company Proton System (Belgrade). The agreement gives Proton System the right to sell one of...

SloveniaSlovenia

14.02.2008

Ljubljana/Brussels – Slovenia, which took over the EU presidency from Portugal in January, will put its health-care focus on improving the management of cancer, representatives announced on the presidency website...

Germany, SloveniaSlovenia

24.10.2007

Zagreb – Barr-PLIVA d.d.’s German subsidiary AWD.pharma GmbH & Co. KG. has signed an agreement to acquire O.R.C.A.pharm GmbH (“ORCApharm“), a privately owned specialty pharmaceutical company focused on the oncology market in...

SloveniaSlovenia

17.05.2007

Ljubljana – Slovenia’s national prevention scheme has led to a very low rate of new HIV infections. According to Slovenias’ health minister, Andrej Brucan, fewer than one in 1000 people is infected with the AIDS virus.

SloveniaSlovenia

21.11.2006

Zagreb – Consolidation of the generic-drug business is focusing on eastern Europe. So far in 2006, at least eight deals have been announced, including Barr Pharmaceuticals‘ US$2.5-billion acquisition of Croatia‘s Pliva, completed...

SloveniaSlovenia

17.03.2006

Ljubljana - Lek, the wholly-owned Slovenian subsidiary of Sandoz, Novartis' generics business, will once again cut up to 50 jobs through the course of the year. The redundancies are expected to hit all departments except R&D and...

Displaying results 1 to 10 out of 22

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-slovenia/article/barr-to-purchase-pliva-for-22-billion-beating-rival-actavis.html

Events

All Events

Stock list

All quotes

TOP

  • PHARMING (NL)0.48 EUR11.63%
  • MDX HEALTH (B)3.80 EUR10.79%
  • NEUROVIVE PHARMACEUTICAL AB (S)70.00 SEK8.53%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.46 EUR-10.26%

TOP

  • WILEX (D)2.82 EUR243.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)70.00 SEK44.3%
  • Allergy Therapeutics (UK)20.00 GBP34.4%

FLOP

  • HYBRIGENICS (F)1.72 EUR-28.0%
  • PROSENSA (NL)9.67 USD-23.4%
  • PROTHENA PLC (IE)17.79 USD-21.1%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)431.00 GBP656.1%
  • PAION (D)2.42 EUR272.3%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.7%
  • CYTOS (CH)0.27 CHF-92.0%
  • PROSENSA (NL)9.67 USD-70.9%

No liability assumed, Date: 31.07.2014


Current issue

All issues

Product of the week

Products